Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Fineline Cube Mar 2, 2026
Company Drug

InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label

Fineline Cube Mar 2, 2026
Company

Boehringer Ingelheim Surpasses Bayer in Pharma Sales with EUR 20.8 Billion in 2023

Fineline Cube Apr 17, 2024

Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing...

Company Drug

KPC Pharmaceuticals Gets NMPA Green Light for Clinical Trial on Familial Mediterranean Fever Treatment

Fineline Cube Apr 17, 2024

Yunnan-based KPC Pharmaceuticals Inc., (SHA: 600422) has announced that it has received clinical trial approval...

Company Deals

AbbVie Partners with Medincell for Development of Long-Acting Injectable Therapies

Fineline Cube Apr 17, 2024

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has entered into a partnership with France-based...

Company Drug

Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech

Fineline Cube Apr 17, 2024

GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has...

Company

J&J’s Medical Technology Sector Rises 6.3% YOY Despite China’s VBP Impact

Fineline Cube Apr 17, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has reported its financial results for the first quarter...

Policy / Regulatory

China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds

Fineline Cube Apr 17, 2024

The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court,...

Policy / Regulatory

Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance

Fineline Cube Apr 17, 2024

The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court,...

Drug Policy / Regulatory

China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...

Company Drug

AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial

Fineline Cube Apr 17, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year...

Medical Device Policy / Regulatory

China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...

Company Deals

Beijing Airdoc Leads RMB 500 Million Joint Venture to Invest in AI-Powered Healthcare

Fineline Cube Apr 17, 2024

Beijing Airdoc Technology Co., Ltd., a leading artificial intelligence (AI)-powered ophthalmology device company, has announced...

Company Drug

Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment

Fineline Cube Apr 17, 2024

Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of...

Company Drug

China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment

Fineline Cube Apr 17, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...

Company

Roche China’s Talent and Culture Vice President Chen Yanli Departs for New Opportunities

Fineline Cube Apr 16, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the departure of Chen Yanli, who...

Company Drug

Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor

Fineline Cube Apr 16, 2024

Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...

Company Drug

Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers

Fineline Cube Apr 16, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...

Company Drug

Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial

Fineline Cube Apr 16, 2024

Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial...

Company Drug

Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial

Fineline Cube Apr 16, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III...

Policy / Regulatory

EU Set to Investigate China’s Medical Device Procurement Practices Amid Fairness Concerns

Fineline Cube Apr 16, 2024

The European Union (EU) is reportedly gearing up to launch an investigation into medical device...

Company Deals

Ningbo Menovo Partners with University of Michigan to Develop GLP-1 Delivery System

Fineline Cube Apr 16, 2024

Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538), a China-based company, has announced a strategic partnership...

Posts pagination

1 … 336 337 338 … 628

Recent updates

  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
  • Sino Biopharma’s Rovadicitinib Wins NMPA Approval – First‑in‑Class JAK/ROCK Inhibitor for Myelofibrosis
  • Antengene’s XPOVIO Secures Second South Korea Reimbursement – Selinexor Combo Approved for Multiple Myeloma
  • Hangyu Pharma’s Sosimerasib Wins NMPA Approval – First KRAS G12C Inhibitor for Post‑Therapy NSCLC in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Company Drug

InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label

Company Drug

Sino Biopharma’s Rovadicitinib Wins NMPA Approval – First‑in‑Class JAK/ROCK Inhibitor for Myelofibrosis

Company Drug

Antengene’s XPOVIO Secures Second South Korea Reimbursement – Selinexor Combo Approved for Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.